A293780 Stock Overview
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
AptaBio Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩9,160.00 |
| 52 Week High | ₩15,490.00 |
| 52 Week Low | ₩4,930.00 |
| Beta | 2.12 |
| 11 Month Change | -22.31% |
| 3 Month Change | 56.05% |
| 1 Year Change | -10.11% |
| 33 Year Change | -81.66% |
| 5 Year Change | 9.05% |
| Change since IPO | -52.90% |
Recent News & Updates
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12
Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Recent updates
Is AptaBio Therapeutics (KOSDAQ:293780) Using Too Much Debt?
Jul 12Here's Why AptaBio Therapeutics (KOSDAQ:293780) Can Manage Its Debt Despite Losing Money
Mar 26Do Institutions Own AptaBio Therapeutics Inc. (KOSDAQ:293780) Shares?
Feb 23Companies Like AptaBio Therapeutics (KOSDAQ:293780) Can Afford To Invest In Growth
Jan 01
Shareholder Returns
| A293780 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -9.2% | 1.3% | 4.1% |
| 1Y | -10.1% | 35.8% | 5.2% |
Return vs Industry: A293780 underperformed the KR Biotechs industry which returned 34.4% over the past year.
Return vs Market: A293780 underperformed the KR Market which returned 2.5% over the past year.
Price Volatility
| A293780 volatility | |
|---|---|
| A293780 Average Weekly Movement | 17.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.0% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A293780's share price has been volatile over the past 3 months.
Volatility Over Time: A293780's weekly volatility has increased from 11% to 17% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2009 | n/a | Jin Soo | www.aptabio.com |
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH).
AptaBio Therapeutics Inc. Fundamentals Summary
| A293780 fundamental statistics | |
|---|---|
| Market cap | ₩204.26b |
| Earnings (TTM) | -₩11.19b |
| Revenue (TTM) | ₩941.61m |
216.9x
P/S Ratio-18.3x
P/E RatioIs A293780 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A293780 income statement (TTM) | |
|---|---|
| Revenue | ₩941.61m |
| Cost of Revenue | ₩824.84m |
| Gross Profit | ₩116.77m |
| Other Expenses | ₩11.31b |
| Earnings | -₩11.19b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -501.75 |
| Gross Margin | 12.40% |
| Net Profit Margin | -1,188.23% |
| Debt/Equity Ratio | 25.2% |
How did A293780 perform over the long term?
See historical performance and comparison